← Evidence map

ArticleFrontiers in oncology2026

Real-world evidence of baseline soluble CD25 as a prognostic biomarker and indicator of differential EGFR-TKI benefit in stage IV lung adenocarcinoma.

Huiru Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Real-world evidence of baseline soluble CD25 as a prognostic biomarker and indicator of differential EGFR-TKI benefit in stage IV lung adenocarcinoma. | OpenQuestion